Match Document Document Title
US20090011990 CARBOHYDRATE FRACTION AND USE THEREOF FOR A FLAT POSTPRANDIAL GLUCOSE RESPONSE  
The invention relates to a combination of heat-treated nutritional composition having a carbohydrate fraction comprising a) 5-30 wt % of one or more monosaccharides selected from galactose, ribose...
US20120028891 METHODS OF PROMOTING OR MAINTAINING AN ANABOLIC STATE IN A FEMALE ANIMAL  
The present invention is related to methods of promoting or maintaining an anabolic state in a female animal. The methods comprise administering a composition to the female animal, with the...
US20100143382 MODULATION OF RHAMM (CD168) FOR SELECTIVE ADIPOSE TISSUE DEVELOPMENT  
Herein is described the methods and compositions for modulation of Rhamm, also known as CD 186, and its effects on wound repair, muscle differentiation, bone density and adipogeneisis through its...
US20150190466 METHODS OF TREATING METABOLIC DISEASE  
The invention provides methods for treating metabolic disease in a subject and methods for increasing the expression of ILDR2 in a subject. The invention further provides a method for identifying...
US20070275382 Biomarkers for the Efficacy of Somatostatin Analogue Treatment  
Gene expression assays were performed using tissues of monkeys treated with the somatostatin analogue pasireotide at sub-therapeutic dose for 14 days. The assays were analyzed to identify the...
US20120214735 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS  
Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment,...
US20130225484 STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF  
The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention...
US20130296225 Microcrystalline Y Receptor Agonists  
The disclosure provides microcrystals of Y receptor agonists; microcrystalline pellets of Y receptor agonists, and microcrystalline suspensions of Y receptor agonists. Pharmaceutical compositions...
US20140301974 EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS COMPRISING SAME  
The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and...
US20100249023 ISOFLAVONE FORMULATION  
This invention relates to the formulations of isoflavones with soluble carrier proteins, for example whey proteins. The formulations display increased lipid modulating activity without increased...
US20130324460 FIBROBLAST GROWTH FACTOR 21 VARIANTS  
This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods...
US20130085098 FIBROBLAST GROWTH FACTOR 21 VARIANTS  
This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods...
US20150011466 APJ Receptor Compounds  
The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G...
US20120121602 NOVEL PROTEINS  
Provided herein are four polypeptides, named PRT5, PRT6, PRT7 and PRT8, the nucleic acids encoding the same, compositions comprising the proteins, as well as their uses in therapeutic and...
US20070065456 Nutritional supplements  
Nutritional supplement formulations are disclosed, such as nutritional supplement formulations that include Wasabia japonica. Methods for using the same to supplement a human diet are also disclosed.
US20120028888 APJ RECEPTOR COMPOUNDS  
The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G...
US20100196400 GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF  
The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules...
US20100183610 GENETIC POLYMORPHISMS ASSOCIATED WITH ALZHEIMER'S DISEASE, METHODS OF DETECTION AND USES THEREOF  
The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's Disease. In particular, the present invention relates to nucleic acid molecules...
US20070243135 METHOD OF TREATING FETAL GROWTH RETARDATION AND PLACENTAL ISCHAEMIA AND INSUFFICIENCY  
A method for treating intrauterine growth retardation in an animal, such as a human being, is disclosed comprising administration of a lysine composition.
US20150141327 FIBROBLAST GROWTH FACTOR 21 VARIANTS  
This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for...
US20130165370 Counteracting Drug-Induced Obesity Using GLP-1 Agonists  
The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.
US20150038402 MODULATORS OF PROTEASE ACTIVATED RECEPTORS  
The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or...
US20120028890 ACID CONTAINING LIPID FORMULATIONS  
The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic...
US20100285152 COMPOSITION FOR IMPROVING LIVER METABOLISM AND DIAGNOSTIC METHOD  
There is a need to develop a treatment for metabolic syndrome, which is directed to maintaining healthy liver metabolism and not indirectly through weight loss. The present invention provides a...
US20100209518 MICRO-PARTICLES, BLOOD-SUBSTITUTE AND METHOD FOR FORMING SAME  
A method for forming micro-particles is provided. The method includes the steps of: —providing a first solution which includes at least an anion; —providing a second solution which includes at...
US20110230398 Apolipoprotein C-II or its active fractions for the prevention or treatment of obesity and related metabolic disorders  
Apoliporotein C-II or any active fraction of its amino acid sequence that activates lipoprotein lipase (LPL) in mammals. Increase in activity of LPL can increase expenditure of energy, and...
US20070224300 WEIGHT LOSS COMPOSITIONS USING CITRUS PEEL EXTRACT AND EURYCOMA LONGFOLIA  
A combination of Eurycoma longifolia and citrus peel extract are provided in a supplement to promote weight loss and help dieters maintain high energy levels by reducing the body's normal shift to...
US20140187470 Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders  
The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a...
US20110086031 Inhibition Of The Activity Of The Capsaicin Receptor In The Treatment Of Obesity Or Obesity-Related Diseases And Disorders  
The present invention provides a method of treating diseases or disorders benefiting from inactivating or down-regulating the activity of the capsaicin receptor in a mammal by inhibiting the...
US20150174266 APROTININ POLYPEPTIDES FOR TRANSPORTING A COMPOUND ACROSS THE BLOOD-BRAIN BARRIER  
The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as...
US20110171128 APROTININ POLYPEPTIDES FOR TRANSPORTING A COMPOUND ACROSS THE BLOOD-BRAIN BARRIER  
The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides derived from aprotinin and from aprotinin analogs as well as...
US20060241030 Irs modulators  
This invention is directed to a general method for the chronic treatment, potential cure, or prevention of various metabolic and related diseases in people, including diabetes, by modulating IRS2...
US20120064058 COMPOSITIONS FOR PROTEIN-BASED DIETARY PRODUCTS  
A human use dietary product composition to reduce fat body mass without substantially reducing lean body mass, in obese or overweight patients includes a protein component and an amino acid...
US20130280231 COMPOSITION FOR PREVENTING OR TREATING OBESITY  
Provided is a composition for preventing or treating obesity, and more particularly, a composition for preventing or treating obesity in order to treat or improve states of obese patients...
US20130210704 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF  
The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition...
US20140315795 Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types  
The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic...
US20060210650 Supplemental dietary composition for promoting weight loss  
Compositions, and methods for administering the same to humans, are provided for the promotion of healthy fast weight loss while providing an excellent source of calcium and containing...
US20140205600 METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR  
The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is...
US20120183540 METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR  
The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is...
US20060189512 Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging  
Compositions are disclosed which contain therapeutically effective amounts of phlorizin extract for effecting modification of blood glucose and insulin, for facilitating weight loss, preventing...
US20060100145 Human chondroosteomodulin (tig2), production, and use for the treatment or diagnosis of bone diseases, cartilage diseases, cartilage diseases, obesity, inflammatory diseases, and skin diseases  
The invention relates to the polypeptide COM and its derivatives, and methods for its preparation and recovery in a pure or partially purified form from body fluids and tissues, and its use as a...
US20140287001 Compositions Useful For The Treatment Of Gastrointestinal Disorders  
This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by...
US20100203176 METHOD FOR REDUCING WEIGHT IN A SUBJECT  
A method is provided for reducing weight in a subject by administering an effective amount of a composition comprising omega-3 polyunsaturated fatty acid (PUFA), at least one of L-arginine,...
US20140011730 Melanocortin Receptor Ligands Modified with Hydantoin  
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the...
US20120141448 Method for increasing muscle mass and strength  
Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve...
US20050186278 Gastroprotected formulations containing alph-amylase inhibitors  
Disclosed are gastroresistant formulations of phaseolamin characterized in that the enteric coating consists of shellac or other coatings compatible with nutritional use.
US20050239706 Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject  
The invention provides compositions and methods to modulate fat storage and weight loss in a subject. In certain aspects of the invention, fat storage (adiposity) and weight loss is modulated by...
US20100267626 METHODS AND COMPOSITIONS FOR MEASURING WNT ACTIVATION AND FOR TREATING WNT-RELATED CANCERS  
The present application describes methods of regulating or modulating (e.g., antagonizing or inhibiting) Wnt signaling by administering Axin stabilizers. The application also describes methods of...
US20060276410 COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV  
Compounds that selectively inhibit dipeptidyl peptidase-IV over closely related dipeptidyl peptidases are those of Formula (I): as well as pharmaceutically acceptable salts thereof, cyclic isomers...
US20110144007 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES  
There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as...